Boule Diagnostics AB (publ) (STO:BOUL)

Market Cap	157.66M -56.4%
Revenue (ttm)	489.70M -12.3%
Net Income	-3.80M
EPS	-0.10
Shares Out	38.83M
PE Ratio	n/a
Forward PE	4.93
Dividend	n/a
Ex-Dividend Date	n/a

Volume	31,225
Average Volume	46,636
Open	4.300
Previous Close	4.300
Day's Range	4.020 - 4.300
52-Week Range	3.980 - 10.600
Beta	0.28
RSI	34.98
Earnings Date	Feb 11, 2026

About Boule Diagnostics AB

Boule Diagnostics AB (publ) develops, manufactures, and markets instruments and consumable products for blood diagnostics in the United States of America, Asia, Eastern Europe, Latin America, Western Europe, Africa, and the Middle East. The company provides hematology analyzers, reagents, controls, and calibrators, under the Swelab, and Medonic brands; and veterinary hematology and clinical chemistry analyzer systems, as well as reagents and panels under the Exigo brand. It serves small and medium-sized hospitals, clinics, laboratories, and vet...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1956
• Employees: 200
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: BOUL

Financial Performance

In 2025, Boule Diagnostics AB's revenue was 489.70 million, a decrease of -12.31% compared to the previous year's 558.46 million. Losses were -3.80 million, -98.72% less than in 2024.